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Abstract 
Background: early diagnosis of NEC may improve prognosis but there are no proven biomarkers. 
Objective: to investigate changes in faecal volatile organic compounds (VOCs) as potential 
biomarkers for NEC.
Design: multicentre prospective study
Settings: 8 UK Neonatal Units
Patients: preterm infants <34 weeks gestation
Methods: daily faecal samples were collected prospectively from 1,326 babies of whom 49 
subsequently developed definite NEC. Faecal samples from 32 NEC cases were compared to 
samples from frequency-matched controls without NEC. Headspace, solid phase micro-extraction 
gas chromatography/mass spec rometry was performed and VOCs identified from reference 
libraries. VOC samples from cases and controls were compared using both discriminant and factor 
analysis methods. 
Results: VOCs were found to cluster into 9 groups (factors), three were associated with NEC and 
indicated the possibility of disease up to 3-4 days before the clinical diagnosis was established. For 
one factor, a one standard deviation increase increased the odds of developing NEC by 1.6 times; a 
similar decrease of the two other factors was associated with a reduced risk (OR 0.5 or 0.7, 
respectively). Discriminant analyses identified five individual VOCs, which are associated with NEC 
in babies at risk, each with an AUROC of 0.75-0.76, up to four days before the clinical diagnosis was 
made.
Conclusions: Faecal VOCs are altered in preterm infants with NEC. These data are insufficient to 
enable reliable cotside detection of babies at risk of developing NEC and further work is needed 
investigate the role of VOCs in clarifying the aetiology of NEC. 
Keywords: necrotising enterocolitis; preterm infants; volatile organic compounds; longitudinal 
discriminant analysis.
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Introduction
Necrotising enterocolitis (NEC) is the commonest gastrointestinal emergency in premature infants, 
occurring in up to 8% of admissions with to 40% mortality.1-3 This has not significantly improved 
over recent decades3, 4 despite overall improvements in neonatal intensive care and survival3-5 and 
it is possible that the incidence and mortality from NEC are increasing as more preterm infants 
survive.3-5 In addition, NEC is associated with significant morbidity in up to 50% of survivors; either 
due to the disease itself6, 7 or the complications of prolonged parenteral nutrition, surgical 
procedures and short bowel syndrome.3, 8 Survivors of severe NEC are more likely to have 
neurodevelopmental impairment. 3, 9, 10 Despite this, the pathogenesis is uncertain and there is no 
specific treatment. Conservative therapy is limited to discontinuing enteral feeding, antibiotics and 
supportive care. In advanc d disease, surgery to remove affected bowel is a further option.3 
Early detection of NEC is vital to limit progression to advanced fulminant disease. However, 
establishing the diagnosis in the prodrome is difficult because clinical features and investigations 
are often inconclusive. Diagnostic investigations, such as abdominal radiographs, only identify 
established disease and in fulminant NEC conservative management is often ineffective at 
preventing disease progression.
Potential biomarkers for NEC including CRP,11 calprotectin,12 breath hydrogen concentration,13 IL6 
and IL814 have been investigated, but have a limited role in detecting early disease.12, 15 The likely 
aetiology of NEC is a result of defective interactions between the intestinal microbiota and the 
host’s response and it has been suggested that high-throughput sequencing technology may enable 
the detection of  an early diagnosis biomarker.13 Detection of faecal biochemical changes that 
predict the onset of NEC would enable the instigation of early treatment measures which may 
reduce disease severity and limit morbidity and mortality.
Volatile organic compounds (VOCs) have a low boiling point (and high vapour pressure) and readily 
enter the vapour phase. VOCs are emitted from many bodily fluids and contribute to their smell 
(e.g. faeces).16 Faecal VOCs are produced by digestion and/or fermentation of intestinal luminal 
contents and are influenced by the microbiota and diet.17 Faecal VOCs have a similar, stable pattern 
in healthy adults,18 but there are characteristic changes in VOC patterns in some intestinal diseases. 
18-21 We have previously examined faecal VOCs in preterm infants22 and reported a pilot study that 
showed a characteristic change in VOC patterns in babies developing NEC. 23 De Meij et al. used an 
electronic nose to study faecal gases, and suggested the output could be used to diagnose NEC.24
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We aimed to investigate further the pattern of faecal VOCs in a larger, prospective, multi-centre 
study, comparing VOCs in apparently healthy preterm infants developing NEC with those without 
NEC.
Methods
Participants
Between November 2011 and October 2013 all newborns <34 weeks gestation (and therefore at 
greater risk of NEC), admitted to eight UK neonatal units [Birmingham Heartlands, Birmingham 
Women’s, Liverpool Women’s, Royal Shrewsbury, Royal Wolverhampton, Sheffield Teaching, 
University Hospital Coventry and Warwickshire, University Hospital Leicester], were considered for 
recruitment. Babies were excluded if they were unlikely to survive or had significant 
gastrointestinal anomalies. No centre used probiotics as routine prophylaxis at the time of study.
Parents of potential recruits were approached by a research midwife who obtained written 
informed consent. Daily faecal samples were collected, if available, from recruitment until NEC was 
diagnosed or until discharge. Samples were placed in 7ml glass vials (Fisher, Loughborough, UK) and 
immediately frozen at -20oC. We have previously shown that there is no significant change in VOCs 
in samples stored for between 1 week, and 12 months at -20C.25 Batched samples were transported 
on dry ice at regular intervals to the research laboratory. 
Demographic and clinical data on mode of delivery, feeding, antibiotic exposure, respiratory 
support and episodes of illness were collected. Babies with possible NEC were identified by the 
clinical team caring for the baby and the NEC grade was subsequently classified by consensus 
between that team and the independent study team using modified Bell’s criteria.26 Controls did 
not develop NEC of any grade. Approximately two control babies were frequency matched to each 
case of NEC with Bell’s criteria IIa or greater (i.e. definite NEC): matching was based on 
demographic factors including mode of delivery, gestational age at birth, birth weight, sex, age at 
sampling, mode of feeding and antibiotic exposure. Where possible we identified samples from six 
days prior to the definitive diagnosis of NEC. For controls, a day equivalent to the NEC diagnosis 
date was determined, and samples were analyzed from the previous 6 days.
The study was sponsored by University of Birmingham and approved by West Midlands Research 
Ethics Committee (11/WM/0078).
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Laboratory methods
We have previously reported the laboratory method used.27 50-100mg of faeces was transferred to 
10 ml glass vials (Sigma-Aldrich, Dorset, UK) and analyzed by headspace solid phase micro-
extraction (SPME). A PerkinElmer Clarus 500 gas chromatography/mass spectrometry (GC/MS) 
quadrupole benchtop system (Beaconsfield, UK) was used with a Combi PAL auto-sampler (CTC 
Analytics, Switzerland); a Zebron ZB-624 GC column with inner diameter 0.25 mm, length 60 m, film 
thickness 1.4 μm (Phenomenex, Macclesfield, UK); carrier gas was 99.996% pure helium (BOC, 
Sheffield, UK). Samples were pre-incubated for 30 minutes at 60oC prior to exposure to a pre-
conditioned 85μm Carboxen®/Polydimethylsiloxane SPME fiber (Sigma-Aldrich, Dorset, UK). GC 
oven initial temperature was 40oC, held for 1 minute before ramping to 220oC at a rate of 5oC/min 
and held for 13 min (total run time - 50 min). Solvent delay was set for the first 6 min. The MS was 
operated in electron impact ionization EI+ mode, scanning from ion mass fragments 10- 300 m/z 
with an inter-scan delay of 0.1 sec and a resolution of 1000 at full width at half maximum (FWHM). 
Helium gas flow rate was 1 ml/min. Instrument sensitivity was determined using 2-pentanone with 
limit of detection 3 times the signal/noise ratio. This laboratory analysis was conducted between 
November 2013 and August 2014.
Sample VOCs were identified using Automated Mass Spectral Deconvolution System (AMDIS-
version 2.71, 2012) software and the NIST mass spectral library (version 2.0, 2011) in conjunction 
with the R package Metab.28 IUPAC names were assigned to VOCs.
Statistical methods 
Peak area values for VOCs, obtained from AMDIS, were log-transformed and normalized. There is 
no widely accepted approach for treatment of values below the detection threshold. In this study, 
VOC values below the detection threshold were given an abundance of -3 (equivalent to three 
standard deviations below the mean), which corresponds to <1% for normally distributed data. 
Within sample analysis of VOCs was performed independent of case/control status. Within the 
VOCs identified we established patterns using principal component analysis (PCA) to produce a 
smaller number of variables (factors) which captured most of the data variability.  PCA uses the 
correlation matrix to identify compounds that are strongly correlated to one another and divide 
them into factors (Table s1-s3 for examples). Each factor can be expressed as a linear combination 
of the VOCs. Using factors rather than individual VOCs avoided the overfitting problems associated 
with fitting a model with more predictors than events.  A similar approach was followed by de Meij 
et al., 24 with the distinction that here the factors were allowed to be correlated with each other 
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following a non-orthogonal rotation process (promax rotation power of 4, SPSS version 23).  We 
chose this method to reflect different unknown biological mechanisms by which these factors 
might contribute to NEC and could be associated with each other. Factors were investigated for 
biological plausibility by regressing against demographic variables. All regression analysis containing 
multiple data points per infant used robust standard errors in Stata (version 14) and account for the 
longitudinal nature of the data by clustering by infant. Logistic regression assessed the ability of 
each factor t  predict NEC.
A recently-developed longitudinal discriminant analysis (LoDA) method29-31 assessed the association 
of individual VOCs with the risk of developing NEC. Linear mixed models were fit separately to each 
VOC for both NEC and control samples adjusting for age, gestation, delivery type, sex and a random 
effect intercept.  Discriminant analysis was used for each VOC to determine whether the patient 
should be classified as at risk of NEC: 1000 bootstrap datasets were generated to evaluate the 
sensitivity, specificity and area under the curve (AUC).  Mean lead time was calculated as the mean 
time before diagnosis when the infant was correctly scored at risk of NEC.
The classification scheme (Figure 1) was designed to predict the risk of NEC. The threshold chosen 
was determined by receiver operating characteristic (ROC) curve analysis. When the data showed a 
baby’s risk of developing NEC was above the chosen threshold they were classified as an NEC case 
(if this were conducted in real time this would allow a clinician to consider early intervention). 
Whilst a baby’s risk remained below the threshold, they were provisionally classified as not 
developing NEC and their risk were reassessed with the addition of the next day’s data.
Results
1,326 premature babies were recruited. 49 babies were diagnosed with NEC Bell’s stage IIa or 
greater and 32 of these had adequate sample collection for analysis; these were matched with 70 
controls. There was no evidence of concomitant sepsis in any of the cases and all the controls were 
deemed healthy at the time of sampling. Neonates did not defaecate daily: a median of 2 samples 
were analyzed for both cases and controls. We collected 81 samples from cases and selected 163 
from controls within the 6-day time window (Supplementary Table S4) following the matching 
procedure described above. See Table 1 for demographic data.
Page 6 of 20
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Table 1 Summary of demographic and clinical factors 
   NEC Control  Test Probability
   32 70   
Sex      Chi-sq  0.05
Male (n[ %[])   13 [41] 43 [61]
Birth weight (median [IQR], g  795 [976] 1045 [541]
 Mann 
Whitney 0.0002
Mode of delivery      Chi-sq 0.160
Vaginal (n [%})   15 [47] 27 [39]
Missing data   0 1 [1.4]   
Feeding pattern (n[%])    Chi-sq 0.65
Breast+formula   25 [78] 52 [74]   
Exclusive breast 6 [19] 13 [19]
Exclusive formula   1 [3] 5 [7]   
Postnatal age at first sample (median [IQR]), d 21 [22] 22  [27]   Mann Whitney 0.66
Duration of gestation (median,[IQR]), w 26.7[2.9] 28.4 [3.8]
  Mann 
Whitney 0.002
Post conception at first sample (median,[IQR]), w 30.6[4.4] 32.4[3.7]
   Mann 
Whitney 0.02
AB use before sampling
 32 70   
Bell's grade       
2   14 NA   
3   18 NA   
 
Number of samples  
 
Number of samples
Days before 
diagnosis Control NEC  Distribution  Control  NEC
1 34 16  Median 2 2
2 22 8  Q1 1.5 2
3 42 20  Q3 3.5 3
4 18 14  IQR 2 1
5 31 16     
6 19 8     
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50 headspace VOCs were identified (prevalence 45-99%).  On average NEC cases had 35.8 VOCs 
identified per sample and controls 36.4. Two VOCs with similar structures and retention times 
(30.73 and 30.90 minutes, respectively) were difficult to resolve and their data were combined. 
We identified 9 different factors (groups of VOCs) that had correlated abundances and thus might 
represent a common metabolic (examples in Supplementary Tables S1-3.) or demographic factor 
(Table 2).  They were investigated for biological plausibility and 7 of the 9 were associated with 
demographic variables linked to NEC: birthweight (factors 1, 6 and 9), formula feed (factor 2 and 9), 
postnatal age (factor 4), gender (factor 3) and postconception age (factors 5 and 8), biochemical 
factors (factor 7).   Multiple logistic regression identified three predictors of NEC (factors 4, 5 and 
8), from which a ROC was generated. A one standard deviation increase in factor 4 increased the 
chances of NEC (odds ratio (OR) 1.66 [95% confidence interval (CI) 1.13, 2.43].  Increases in factor 5 
and 8 were associated with a reduced risk of NEC (OR 0.47 [95% CI 0.30, 0.78] and 0.73 [95% CI 
0.53, 0.99]), respectively.  Area under the ROC curve was 0.69 [95% CI 0.62, 0.76]. Results 
separated by day are shown in Table 3. 
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Table 2 Statistical summary variables (group) observed in the VOC profiles  
Group VOCs in the group 
(+)=positive direction  (-)negative direction
Demographics associated with 
the group 
1 (+) (E)-hex-2-enal  
(+) heptan-2-one
(+) heptanal
(+) 2-pentylfuran
(+) (Z)-hept-2-enal
(+) dec-1-en-3-one
(+) octanal
(+) 5-ethylcyclopentene-1-carbaldehyde
(+) (E)-oct-2-enal
(+) nonan-1-ol
(+) prop-2-enal 
(+) propanal 
(+) 2-ethylfuran
(+) pent-1-en-3-one
(+) pentanal
(+) (E)-pent-2-enal
(+) hexanal
Birthweight
2 (+) ethanol
(+) propan-1-ol
(+) butane-2,3-dione 
(-) ethyl acetate
(+) acetic acid
(+) propyl acetate
(+) propanoic acid
(+) propyl propanoate 
Post-conceptual age, breast 
feeding, gender
3 (+) 2,2,4,6,6-pentamethylheptane
(+) 2,2,4,4-tetramethyloctane
(+) 2,6,10-trimethyl dodecane
(+) 3,3,4-trimethyl decane
Not associated with any 
recorded demographic 
variables
4 (+) 3-methylsulfanylpropanal 
(+) benzaldehyde
(+) 2-phenylacetaldehyde 
(+) 2-methylpropanal
(-) 3-methylbutanal
(-) 2-methylbutanal
Formula milk, age
5 (-) heptan-4-one
(+) methanedithione 
(+) butan-2-one
Post-conceptual age
6 (+) propan-2-one 
(-) propan-2-ol 
Birthweight
7 (+) ethylbenzene
(+) xylene
(+)(4R)-1-methyl-4-prop-1-en-2-ylcyclohexene 
Not associated with any 
recorded demographic 
variables
8 (+) 3-methylbutanoic acid
(+) 2-methylbutanoic acid
(+) butanoic acid
Post-conceptual age
9 (+) 6-methyl-5-hepten-2-one 
(+) 3,4-dimethylcyclohexan-1-ol
(+) 4-acetyl-2,3,4,5,5-pentamethyl2-cyclopenten-1-one 
Formula use, birthweight
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On average, LoDA was able to predict NEC for each VOC individually up to 4 days before the 
diagnosis of NEC (e.g., 95% CI for (Z)-hept-2-enal = (2.79, 4.42) days). 28 VOCs could classify infants 
reasonably with an AUC greater than 0.7 (Table 4). The best performing VOCs could identify 
approximately 70% of NEC cases, and also correctly identified approximately 70% of controls using 
the cut off which was chosen as the point on the ROC curve closest to the top left corner (the five 
VOCs with the best level of discrimination are shown in Figure 2).
Table 3 Mean values of the area under the ROC curve in the prodromal period
 Day -6 Day -5 Day -4 Day -3 Day -2 Day -1
0.70 0.76 0.45 0.70 0.74 0.74AUC
[0.47, 0.94] [0.61, 0.91] [0.24, 0.66] [0.54, 0.85] [0.56, 0.93] [0.59, 0.90]
No. 
observations
27 47 31 59 30 50
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Table 4 Prediction accuracy for VOCs with AUC >.7 using longitudinal discriminant analysis
Cutoff Sensitivity Specificity AUC Mean Lead Time (d)
(Z)-hept-2-enal
0.37 0.78 0.68 0.76 3.68
pent-1-en-3-one
0.36 0.72 0.73 0.76 3.64
2-ethylfuran
0.38 0.71 0.73 0.76 3.59
pentanal
0.36 0.72 0.73 0.75 3.51
2-pentylfuran
0.37 0.73 0.71 0.75 3.47
dec-1-en-3-one
0.37 0.70 0.73 0.75 3.99
2,6,10-trimethyl dodecane
0.39 0.71 0.72 0.74 4.04
(E)-oct-2-enal
0.36 0.72 0.71 0.74 3.76
2-methylbutanoic acid
0.40 0.74 0.67 0.74 3.64
2,2,4,6,6-pentamethylheptane
0.40 0.69 0.74 0.74 3.91
nonan-1-ol
0.37 0.72 0.69 0.74 3.88
2-methylpropanal
0.35 0.71 0.70 0.73 3.70
3-methylbutanoic acid
0.39 0.71 0.67 0.73 3.61
3-methylsulfanylpropanal
0.38 0.68 0.71 0.73 3.90
butan-2-one
0.38 0.72 0.68 0.72 3.62
butanoic acid
0.35 0.71 0.70 0.72 3.94
propyl acetate
0.37 0.74 0.65 0.72 4.00
heptanal
0.36 0.70 0.69 0.72 3.58
propan-1-ol
0.36 0.69 0.70 0.72 3.96
2,2,4,4-tetramethyloctane
0.40 0.68 0.72 0.72 3.93
ethanol
0.37 0.67 0.73 0.72 4.09
(4R)-1-methyl-4-prop-1-en-
ylcyclohexene  
 0.39 0.66 0.71 0.72 3.73
(E)-hex-2-enal
0.36 0.68 0.70 0.71 3.64
(E)-pent-2-enal
0.37 0.71 0.67 0.71 3.65
propan-2-one
0.35 0.71 0.66 0.71 3.48
octanal
0.35 0.70 0.67 0.71 3.55
propan-2-ol 0.37 0.68 0.66 0.71 3.54
2-phenylacetaldehyde  0.37 0.68 0.69 0.71 4.07
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Discussion
We have undertaken GCMS analysis of faecal headspace gases obtained from premature infants at 
risk of NEC in the largest prospective study of its kind. Over 7000 samples were collected from 1326 
babies and pre-diagnosis samples from the 32 babies who subsequently developed NEC were 
identified and produced 9 distinct groups of VOCs (factors). Comprehensive analysis of VOCs found 
three factors (4, 5 and 8) that were associated with NEC.
We have previously shown, in a much smaller study of only 6 NEC cases using a less sophisticated 
analysis, that changes in faecal VOC patterns may occur in the pre-clinical phase of NEC.23 This 
finding has also been demonstrated by using an eNOSE system,24 however the present study 
included almost three times as many cases of NEC than the study by de Meij et al.24 and provided 
detailed analysis of individual VOCs (rather than just changes in the pattern) which allowed us to 
explore, for the first time, the biological plausibility of the changes in VOCs identified.
This biological plausibility, shown by the association of the different factors with demographic 
variables, may represent changes of VOCs produced by biological processes, such as the 
colonisation of the gut by specific bacteria. The association of three of the factors with post-
conceptual age rather than gestational age or postnatal age alone, suggests an interaction between 
the maturation of the gut and bacteria colonisation, which may be protective.
Matching was carried out to take account of all demographic variables considered likely to 
confound the results of the analysis: thus, priority was given to gestation, mode of delivery, place 
of birth and feed type. Despite this adjustment there remained differences in birthweight, sex 
and gestation (Table 1) and perfect matching was not achievable as they were matched to 
available samples at the time that they were suspected of having NEC, to prevent excess frozen 
samples deteriorating prior to analysis. Nevertheless, the linear mixed models involved in the 
longitudinal discriminant analysis adjusted for a number of demographic and baseline factors, 
including age at sampling, gestational age at birth, mode of delivery and sex. 
In the sample analysis of different factors identified within the compounds, we observed that of the 
9 factors identified following PCA, at least three factors were associated with birthweight, but none 
of these was also associated with the diagnosis of NEC. Factor 4 contained six correlated VOCs 
which are associated with formula milk feeds and age (Table 2 and Table s1). The risk of NEC 
increases with the value of Factor 4, thus the VOCs may be biomarkers of NEC. Three of VOCs in 
Factor 4 are methyl-aldehydes: 3-methylbutanal and 2-methylbutanal, are specifically related to the 
metabolism of amino acids, leucine and isoleucine, respectively. Such aldehydes can be converted 
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into their respective acids, 3-methyl and 2-methylbutanoic acid by aldehyde dehydrogenase. These 
two acids are present in Factor 8 which is linked to a decreased risk of NEC. A change in the 
abundance of bacteria or fungi that produce aldehyde dehydrogenase is a possible explanation for 
these findings. 
Bifidobacteria reduce the likelihood of developing NEC.32 In vitro studies have shown that 
Bifidobacteria produce 3-methyl and 2-methyl butanoic acid.32 Thus the occurrence of these VOCs, 
present in Factor 8, might be a reflection of the abundance of Bifidobacteria in the controls. 
Lactobacilli and Bifidobacteria are a source of butanoic acid present in Factor 8:32 thus, the greater 
abundance of butanoic acid in control infants may be a result of the protective effect of these 
bacteria.
Both Bifidobacteria and Lactobacilli produce butan-2-one which was found in Factor 5 also 
negatively associated with NEC. A further VOC in factor 5, methanedithione (carbon disulphide)33 
may also be produced by Bifidobacteria.34 Carbon disulphide has numerous toxic properties, but 
may be beneficial as it inhibits NfkB signalling by binding to IKK, NEMO and NFkB33, 34 and thus has 
anti-inflammatory properties. Bifidobacteria ‘secretions’ have been shown to reduce NfkB in 
transwell experiments.34
Univariate analysis showed several VOCs with abundances which differed between cases and 
controls to such an extent that they appeared to act as biomarkers for NEC 3-4 days before 
diagnosis. Some appeared in the factor analysis, but others were significant although not present in 
Factors 4, 5 or 8. Notable were propanal, pentanal, hexanal: aldehydes identified in Factor 1. 
Aldehydes are associated with Crohn’s disease20 and are thought to arise from lipid peroxidation as 
a consequence of epithelial inflammation. The presence of these compounds may be an earlier 
indicator of enterocolitis. 
Both the LoDA and the factor analysis highlight the fact that a number of VOCs are associated with 
a high risk of developing NEC. The LoDA approach could be extended to consider multiple VOCs 
simultaneously, although a greater sample size would be required. Validation in further datasets 
would be required before the usefulness of individual VOCs as potential biomarkers for 
classification of NEC could be determined.
Although our study is the largest, multicentre, prospective study of its kind, the overall number of 
NEC cases and the number of prodromal samples remained relatively small and interpretation of 
our results needs to reflect this. However, we have demonstrated changes in VOCs between babies 
developing NEC and those who did not, which may offer further insight into the pathophysiology of 
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NEC, particularly if some of these are associated with microbial metabolic pathways. Understanding 
these changes may later form the basis for a diagnostic tool. 
Further studies already underway intend to try to replicate our data (MAGPIE study: 
ISRCTN12554594) and further investigate the role of VOCs in the aetiology of NEC. 
What is already known on this topic?
 NEC is a serious condition with a high mortality and morbidity. There are no known 
biomarkers.
 Early diagnosis may reduce illness severity
 Volatile organic compounds (VOCs) have been suggested as potential biomarkers of NEC
What does this study add?
 This is the largest prospective study investigating potential biomarkers for NEC
 VOCs have moderate sensitivity and specificity for identifying cases of NEC 3-4 days 
before diagnosis
 The biological plausibility of the VOCs identified sheds further light on potential 
mechanisms for the development of NEC
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Legends for Figures
Figure 1: Classification scheme used to identify babies with increased risk of NEC
Figure 2: ROC curves for the best five performing VOCs by AUC (95% CIs) using longitudinal 
discriminant analysis
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Figure 1: Classification scheme used to identify babies with increased risk of NEC 
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Table S1 Spearman’s rank correlation coefficients for compounds in group 4. 
 3-methyl-
sulfanyl-
propanal  
2-methyl 
propanal 
 
Benzene- 
acetalde- 
hyde 
3-methyl  
butanal  
 
Benz-
aldehyde 
2-methyl  
butanal  
 
Methional 1.00       
2-methylpropanal  0.62 1.000     
Benzeneacetalde-
hyde 
0.47 0.47 1.000    
3-methylbutanal 0.38 0.49 0.34 1.00   
Benzaldehyde 0.60 0.50 0.45 0.35 1.00   
2-methylbutanal 0.48 0.68 0.38 0.40 0.39 1.00 
 
Table S2 Spearman’s rank correlation coefficients for compounds in group 5. 
 Butan-2-one  Methanedithione Heptan-4-one 
Butan-2-one 1.00   
Methanedithione 0.39 1.00   
Heptan-4-one -0.14 -0.21 1.00  
 
Table S3 Spearman’s rank correlation coefficients for compounds in group 8. 
 
Table S4 Samples distribution along time line for analysis showing the number of samples available 
on each of the 6 days prior to the day of diagnosis 
 Number of 
patients 
Day -1 Day -2 Day -3 Day -4 Day -5 Day -6 Total  
samples 
Healthy 
control 
70 34 21 41 17 31 19 163 
Confirmed 
NEC 
34 17 9 19 15 16 8 84 
 
 
 2-methylbutanoic acid 3-methylbutanoic acid Butanoic acid 
2-methylbutanoic acid 1.00   
3-methylbutanoic acid 0.68 1.00   
Butanoic acid 0.46 0.33 1.00 
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